Overcoming the limitations of existing T cell therapies
Currently available treatment options are limited for cancer and chronic infections and many patients do not receive adequate therapy. Recently, the transfer of genetically engineered T cells has been shown to be promising for the treatment of such diseases in clinical studies. This immunotherapy approach aims to help the patient’s own immune system to defend the body against diseased cells by utilizing either antigen-specific T cell receptors (TCRs) or chimeric antigen receptors (CARs).
A lack of suitable receptor candidates has been a major limitation of these treatment strategies in the past.
To this end, we have developed a proprietary platform technology for high-throughput cloning and characterization of naturally selected TCRs. Our CAR and TCR platform is fast and flexible and allows for TCR isolation from single T lymphocytes of patient samples in as little as 11 days. With these features, the platform has the potential to become a mainstream tool for truly personalized and broadly applicable targeted immunotherapies.
Our Vision is…
… to make our platform a standard tool for the development of targeted immunotherapies.
… to use our platform for the development of better, highly efficacious and safe immunotherapies.